Nanovibronix (NASDAQ:NAOV) Shares Down 4.5% – Should You Sell?

Posted by Wayne Rhoads on Jan 13th, 2026

Nanovibronix, Inc. (NASDAQ:NAOV – Get Free Report)’s share price traded down 4.5% during trading on Monday . The company traded as low as $4.01 and last traded at $4.1150. 32,840 shares were traded during trading, an increase of 5% from the average session volume of 31,334 shares. The stock had previously closed at $4.31.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Nanovibronix from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Nanovibronix in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Read Our Latest Stock Analysis on Nanovibronix

Nanovibronix Trading Down 4.5%

The stock has a market capitalization of $4.49 million, a price-to-earnings ratio of -0.10 and a beta of 2.05. The business has a 50 day simple moving average of $4.24 and a 200-day simple moving average of $6.15.

Nanovibronix (NASDAQ:NAOV – Get Free Report) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.91) earnings per share for the quarter. Nanovibronix had a negative return on equity of 24.78% and a negative net margin of 275.12%.The company had revenue of $0.72 million for the quarter.

About Nanovibronix

(Get Free Report)

Nanovibronix, Inc is a medical technology company that develops and markets noninvasive, wearable ultrasound devices for therapeutic applications. The company’s core focus lies in wound management and pain relief using its proprietary ultrasonic platform, which delivers low-intensity acoustic energy through lightweight, disposable transducers. Nanovibronix’s products are designed to accelerate tissue repair, reduce inflammation and minimize reliance on pharmaceuticals in both acute and chronic care settings.

The company’s flagship offerings include the Dermacare System for chronic wound therapy and the PainShield System for postoperative pain management.